JANX Stock: Price, Earnings History and SEC Filings
Janux Therapeutics, Inc. (JANX) last traded at $17.47, down 2.02% on the latest session and up 1.1% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.35 against an analyst estimate of $-0.26, a miss of 34.6%.
$17.47 -2.02%
1 month+1.10%
52-week high$35.34
52-week low$12.12
Volume540,038
ExchangeNasdaqGM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
JANX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 6, 2026 | $-0.35 | $-0.26 | -34.62% |
| Mar 2026 | May 7, 2026 | $-0.39 | $-0.50 | +22.00% |
| Dec 2025 | Feb 26, 2026 | $-0.51 | $-0.65 | +21.54% |
| Sep 2025 | Nov 6, 2025 | $-0.39 | $-0.60 | +35.00% |
JANX beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for JANX
SEC filing data is not available right now. You can search for JANX on SEC EDGAR.
JANX news
- Janux Therapeutics (JANX) Stock Looks Above Fair Value Based On SalesOct 29, 2026 · finance.yahoo.com
- Ensign Group (ENSG) Beats Q3 Earnings EstimatesOct 27, 2026 · finance.yahoo.com
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc. (JANX) is a US-listed public company on Nasdaq.